Saturday, October 31, 2026

Moderna Stock Went Down By Over 10% So Far Today

ViaNews Editorial Team

December 9, 2020

Moderna Stock Went Down By Over 10% So Far Today
Shares of Moderna dropped by a staggering 10.12% to $152.67 at 14:31 EST on Wednesday, after two successive sessions in a row of gains. The Nasdaq Stock Market is sliding 1.38% to $12,409.00, after four sequential sessions in a row of gains, on what up until now seems, an all-around negative trend trading session today. Moderna's last close was $169.86, 16.92% below its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1428.1% for the present quarter and 13065.3% for the next. The company's growth estimates for the ongoing quarter is a negative 48.6% and positive 565.7% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $152.67 at 14:31 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way higher than its 50-day moving average of $96.34 and way above its 200-day moving average of $75.22.

Previous days news about Moderna

Early bet on Moderna sees top european fund gain 65% this year. According to Bloomberg Quint on Mon Dec 7, "A Baillie Gifford & Co. health care fund run by an all-female team has surged past peers to a 65% gain this year, largely thanks to a far-sighted bet on medical stock Moderna Inc." Moderna shares rally as Canada doubles vaccine order. According to MarketWatch on Mon Dec 7, "Shares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for has gained 7.8%." Moderna, Pfizer won’t attend white house summit on vaccines. According to Bloomberg Quint on Mon Dec 7, "The two pharmaceutical companies closest to gaining U.S. clearance for a Covid-19 vaccine won't attend a planned White House summit intended to build confidence in the shots." Moderna says Swiss government has increased its Covid vaccine order to 7.5 million doses from 4.5 million. According to MarketWatch on Tue Dec 8, "Moderna Inc. said Tuesday the Swiss government has increased its order for Moderna's COVID-19 vaccine candidate to 7.5 million doses from an original 4.5 million. Moderna said it's on track to start delivering the vaccine as soon as it gets the nod from Swiss regulators. "Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted this month,' the company said in a statement."
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com